{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:37:39Z","timestamp":1762144659944},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s10165-009-0169-x","type":"journal-article","created":{"date-parts":[[2009,4,10]],"date-time":"2009-04-10T05:55:05Z","timestamp":1239342905000},"page":"384-389","source":"Crossref","is-referenced-by-count":2,"title":["A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis"],"prefix":"10.1093","volume":"19","author":[{"given":"Mikio","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,4,11]]},"reference":[{"key":"169_CR1","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.11156","volume":"48","author":"M Bores","year":"2003","unstructured":"Bores M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48:1771\u20134.","journal-title":"Arthritis Rheum"},{"key":"169_CR2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762\u201384.","journal-title":"Arthritis Rheum"},{"key":"169_CR3","first-page":"90","volume-title":"Manual for diagnosis and therapeutic guidelines on evidence-based medicine (in Japanese)","author":"Ministry of Health, Labour and Welfare Study Group","year":"2004","unstructured":"Ministry of Health, Labour and Welfare Study Group. Manual for diagnosis and therapeutic guidelines on evidence-based medicine (in Japanese). 1st ed. Tokyo: Japan Rheumatism Foundation; 2004. p. 90\u20131.","edition":"1"},{"key":"169_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"169_CR5","first-page":"43","volume":"3360","author":"K Yamasaki","year":"1988","unstructured":"Yamasaki K. Diagnostic criteria for early rheumatoid arthritis of the Ministry of Health and Welfare in Japan (in Japanese). Jpn Med J. 1988;3360:43\u20137.","journal-title":"Jpn Med J"},{"key":"169_CR6","first-page":"1013","volume":"34","author":"S Yamamoto","year":"1994","unstructured":"Yamamoto S, Kashiwazaki S, Nobunaga T. Study on Japan Rheumatism Association diagnostic criteria for early rheumatoid arthritis\u20142. Proposed diagnostic criteria for early rheumatoid arthritis (in Japanese). Ryumachi. 1994;34:1013\u20138.","journal-title":"Ryumachi"},{"key":"169_CR7","first-page":"333","volume":"5","author":"Y Shiokawa","year":"1985","unstructured":"Shiokawa Y, Abe S, Warabi H, Abe S, Kageyama T, Kosaka S, et al. Clinical evaluation of SA96 on rheumatoid arthritis (in Japanese). Jpn J Inflamm. 1985;5:333\u201343.","journal-title":"Jpn J Inflamm"},{"key":"169_CR8","first-page":"1116","volume":"135","author":"Y Shiokawa","year":"1985","unstructured":"Shiokawa Y, Ogawa N, Abe S, Kosaka S, Honma M, Akizuki M, et al. Clinical evaluation of SA96 for RA (in Japanese). Igaku no Ayumi. 1985;135:1116\u201333.","journal-title":"Igaku no Ayumi"},{"key":"169_CR9","first-page":"106","volume":"3","author":"S Kashiwazaki","year":"1987","unstructured":"Kashiwazaki S, Shiokawa Y. Bucillamine: a new immunomodulator. Int J Immunother. 1987;3:106\u201311.","journal-title":"Int J Immunother"},{"key":"169_CR10","first-page":"147","volume":"8","author":"M Goto","year":"1992","unstructured":"Goto M, Yamada T, Nishioka K. The long-term effects of bucillaminein the treatment of early-stage rheumatoid arthritis. Int J Immunother. 1992;8:147\u201351.","journal-title":"Int J Immunother"},{"key":"169_CR11","first-page":"27","volume":"23","author":"M Nagashima","year":"2005","unstructured":"Nagashima M, Shu G, Yamamoto K, Yamahatsu S, Yoshino S. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. Epidemiology of DMARDs treatment in Japan. Clin Exp Rheumatol. 2005;23:27\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"169_CR12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/s10165-006-0527-x","volume":"16","author":"M Iwatani","year":"2006","unstructured":"Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol. 2006;16:376\u201380.","journal-title":"Mod Rheumatol"},{"key":"169_CR13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2165\/00044011-199509050-00006","volume":"9","author":"SY Kim","year":"1995","unstructured":"Kim SY, Lee IH, Bae SC, Yoo DH. Preliminary trial of the efficacy of bucillamine in Korean patients with rheumatoid arthritis. Clin Drug Investig. 1995;9:284\u201390.","journal-title":"Clin Drug Investig"},{"key":"169_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/PL00006849","volume":"17","author":"HA Kim","year":"1997","unstructured":"Kim HA, Song YW. A comparison between bucillamine and d-penicillamine in the treatment of rheumatoid arthritis. Rheumatol Int. 1997;17:5\u20139.","journal-title":"Rheumatol Int"},{"key":"169_CR15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903\u201311.","journal-title":"Lancet"},{"key":"169_CR16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ard.48.5.389","volume":"48","author":"IH Nuver-Zwart","year":"1989","unstructured":"Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulfasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulfasalazine. Ann Rheum Dis. 1989;48:389\u201395.","journal-title":"Ann Rheum Dis"},{"key":"169_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/ard.51.4.461","volume":"51","author":"D Porter","year":"1992","unstructured":"Porter D, Madhok R, Hunter JA, Capell HA. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. Ann Rheum Dis. 1992;51:461\u20134.","journal-title":"Ann Rheum Dis"},{"key":"169_CR18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/bmj.287.6399.1099","volume":"287","author":"VC Neumann","year":"1983","unstructured":"Neumann VC, Grindulis KA, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J. 1983;287:1099\u2013102.","journal-title":"Br Med J"},{"key":"169_CR19","first-page":"1937","volume":"156","author":"P Gadangi","year":"1996","unstructured":"Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Mntesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156:1937\u201341.","journal-title":"J Immunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-009-0169-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:24:55Z","timestamp":1646843095000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-009-0169-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s10165-009-0169-x","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,11]]}}}